US Provisional Patent Application – Dr. Gu Hua
A next-generation antibody therapy for multiple influenza subtypes, enabled by a scalable platform targeting a transcription factor in B-cells to generate high-affinity, high-titer antibodies.
-
Careers • News • Contact us •
- Login
- Français
Platform for producing high-affinity and broadly neutralizing antibodies by disrupting a target in B-cells
March 04 2026
110, ave des Pins West,
Montréal (Québec) Canada
H2W 1R7
514 987-5500
Partners
Research
Platforms
Student life
Admissions
The Institure
- A word from the president
- Our impact
- Our Legacy
- Governance
- Management Committee
- IRCM Awards
- Annual reports
Events
The Clinic
© Montreal Clinical Research Institute, Année.All rights reserves. | Privacy policy | Terms of use | Web site by Agence Riposte
